Am J Psychiatry 162:954-962, May 2005
© 2005 American Psychiatric Association
A Double-Blind, Placebo-Controlled Trial of Sibutramine for Olanzapine-Associated Weight Gain
David C. Henderson, M.D.,
Paul M. Copeland, M.D.,
Tara B. Daley, M.P.H.,
Christina P. Borba, M.P.H.,
Corrine Cather, Ph.D.,
Dana D. Nguyen, Ph.D.,
Pearl M. Louie, M.D.,
A. Eden Evins, M.D.,
Oliver Freudenreich, M.D.,
Doug Hayden, M.A., and
Donald C. Goff, M.D.
OBJECTIVE: Weight gain is commonly observed with olanzapine treatment and can increase the risk for obesity, cardiovascular disease, hypertension, and diabetes mellitus. This study examined the effectiveness of sibutramine, an approved weight loss agent, in overweight and obese subjects taking olanzapine for schizophrenia or schizoaffective disorder. METHOD: Each subject had a DSM-IV diagnosis of schizophrenia or schizoaffective disorder, had been taking a stable dose of olanzapine for at least 4 months, and had a body mass index of  30 kg/m2 or 27 kg/m2 plus at least one cardiovascular risk factor. In a 12-week double-blind, randomized, placebo-controlled study, 37 subjects received placebo or sibutramine (up to 15 mg/day). For the first 8 weeks all subjects participated in weekly group sessions focused on nutrition and behavioral modification. RESULTS: The sibutramine and placebo groups had no significant baseline differences on age, gender, education, ethnicity, diagnosis, weight, body mass index, and blood pressure. At week 12 the sibutramine group had significantly greater losses than the placebo group in weight (mean=8.3 lb, SD=2.4, versus mean=1.8 lb, SD=1.6), waist circumference, body mass index, and hemoglobin A1c. There were no significant differences on most side effects, although the sibutramine group exhibited a mean increase in systolic blood pressure of 2.1 mm Hg (SD=8.5), and anticholinergic side effects and sleep disturbances were at least twice as common in the sibutramine group. CONCLUSIONS: Sibutramine was an effective and well-tolerated adjunct to behavior modification for weight loss in patients with schizophrenia and schizoaffective disorder being treated with olanzapine.
This article has been cited by other articles:
|
|
|
|
 
R.-R. Wu, J.-P. Zhao, X.-F. Guo, Y.-Q. He, M.-S. Fang, W.-B. Guo, J.-D. Chen, and L.-H. Li
Metformin Addition Attenuates Olanzapine-Induced Weight Gain in Drug-Naive First-Episode Schizophrenia Patients: A Double-Blind, Placebo-Controlled Study
Am J Psychiatry,
March 1, 2008;
165(3):
352 - 358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Fenton and M. R. Chavez
Medication-Induced Weight Gain and Dyslipidemia in Patients With Schizophrenia
Focus,
January 1, 2008;
6(2):
246 - 253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Klein, E. M. Cottingham, M. Sorter, B. A. Barton, and J. A. Morrison
A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated With Initiation of Atypical Antipsychotic Therapy in Children and Adolescents
Am J Psychiatry,
December 1, 2006;
163(12):
2072 - 2079.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Fenton and M. R. Chavez
Medication-Induced Weight Gain and Dyslipidemia in Patients With Schizophrenia
Am J Psychiatry,
October 1, 2006;
163(10):
1697 - 1704.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Malone
Medications Associated with Weight Gain
Ann. Pharmacother.,
December 1, 2005;
39(12):
2046 - 2054.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bushe, P. Haddad, R. Peveler, and J. Pendlebury
The role of lifestyle interventions and weight management in schizophrenia
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
28 - 35.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. S. McIntyre and J. Z. Konarski
Obesity and Psychiatric Disorders: Frequently Encountered Clinical Questions
Focus,
October 1, 2005;
3(4):
511 - 519.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2005
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
